Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
10 participants
OBSERVATIONAL
2008-11-30
2011-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study To Determine Safety/Efficacy of Lucentis For Treatment Of Retinal Angiomatous Proliferation Secondary To Age Related Macular Degeneration
NCT00395707
Scotoma Reduction in AMD Patients Treated With Ranibizumab
NCT00467935
Prophylactic Ranibizumab for Exudative Age-Related Macular Degeneration
NCT02302989
Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy
NCT00470977
Efficacy Study of Lucentis in the Treatment of Diabetic Macular Edema
NCT00387582
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
AMD Patients
Ranibizumab
0.05 ml of ranibizumab injected into the eye monthly for one year
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ranibizumab
0.05 ml of ranibizumab injected into the eye monthly for one year
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age \>55 years
* Patients to be included in the study must have AMD with choroidal neovascularization
* BCVA between 20/20 - 20/400
* Lesion size less than or equal to 12 MPS disc areas
Exclusion Criteria
* Pregnancy (positive pregnancy test)
* Premenopausal women not using adequate contraception. The following are considered effective means of contraception: surgical sterilization or use of oral contraceptives, barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel, an IUD, or contraceptive hormone implant or patch
* Prior enrollment in the study
* Any other condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated
* Participation in another simultaneous medical investigation or trial
* Media insufficient to obtain a view
* Other causes of CNV not related to AMD
* Active ocular or peri-ocular infection
* Ocular surgery within 1 month prior to the study
55 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Genentech, Inc.
INDUSTRY
Retina Center, Minnesota
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Abdhish R. Bhavsar, M.D.
President/Physician/Owner
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Retina Center
Minneapolis, Minnesota, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
facility website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FVF4154s
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.